Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Metronomic Selinexor in Select Soft Tissue Sarcomas and Split Dosing of Selinexor in All Soft Tissue Sarcomas

NCT04811196 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT04811196
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04811196 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Metronomic Selinexor in Select Soft Tissue Sarcomas and Split Dosing of Selinexor in All Soft Tissue Sarcomas
Lead sponsor
University Health Network, Toronto
Phase
Phase 1
Overall status
Completed
Start date
March 29, 2021
Completion date
May 15, 2025
Enrollment
56 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial stromal sarcoma, leiomyosarcoma, malignant peripheral nerve sheath tumor (mpnst), soft tissue sarcoma